With your own knowledge and the help of the following document:

Document 1 (Title: Timing Considerations in Breast Cancer Treatment Sequencing): Breast cancer management increasingly incorporates immediate reconstruction options, raising important questions regarding potential impacts on critical adjuvant therapy timelines. Comprehensive analysis of treatment sequences reveals that immediate reconstruction approaches have minimal influence on chemotherapy initiation when appropriate perioperative protocols are followed. Multi-institutional data examining 1,798 breast cancer patients demonstrates that immediate reconstruction resulted in non-significant chemotherapy delays averaging 7.2 days (range 3-12) compared to non-reconstruction cohorts—well within established oncological safety parameters. Complication rate analysis shows that while minor wound complications occur in 12-18% of immediate reconstruction cases, these rarely result in clinically significant treatment delays, with major complications necessitating treatment postponement occurring in only 2.3-3.8% of patients. Notably, reconstruction technique selection influences these outcomes, with tissue expander approaches demonstrating fewer delay-causing complications than autologous techniques in most comparative studies. Implementation of enhanced recovery protocols specifically designed for reconstructive patients has further reduced recovery timeframes, with time-to-chemotherapy metrics continuing to improve in contemporary surgical series. Consultation timing represents a key variable, with multidisciplinary preoperative planning significantly reducing potential conflicts between reconstructive and oncologic priorities. Current clinical pathways incorporating these insights demonstrate that reconstruction decisions can be separated from chemotherapy timing concerns when appropriate perioperative pathways are followed. These findings align with contemporary oncoplastic principles emphasizing that quality of life considerations, including immediate reconstruction options, can be appropriately integrated with oncological priorities including timely systemic therapy. The documented compatibility between immediate reconstruction and timely chemotherapy has important implications for treatment planning and patient decision-making in early-stage breast cancer management.
Document 2 (Title: Growth promoting effects of IGF-1): The first demonstration that exogenous IGF-1 stimulates growth was the administration of purified hormone to hypophysectomised rats. After the biosynthesis of IGF-1 identical to the native hormone, trials of its use in humans were begun; first in adults and then in children. Our group was the first to introduce long term administration of biosynthetic IGF-1 to children with primary IGF-1 deficiency—primary GH insensitivity or LS. The finding that daily IGF-1 administration raises serum alkaline phosphatase, which is an indicator of osteoblastic activity, and serum procollagen, in addition to IGFBP-3, led to long term treatment. Treatment of patients with LS was also initiated in other parts of the world. The difference between us and the other groups was that we used a once daily dose, whereas the others administered IGF-1 twice daily. Table 1 compares the linear growth response of children with LS treated by four different groups. It can be seen that before treatment the mean growth velocity was 3–4.7 cm/year and that this increased after IGF-1 treatment to 8.2–9.1 cm/year, followed by a lower velocity of 5.5–6.4 cm/year in the next two years. (In GH treatment the highest growth velocity registered is also in the first year of treatment.) Figure 5 illustrates the growth response to IGF-1 in eight children during the first years of treatment. Ranke and colleagues reported that two of their patients had reached the third centile (Tanner), as did the patient of Krzisnik and Battelino; however, most patients did not reach a normal final height. The reasons may be late initiation of treatment, irregular IGF-1 administration, underdosage, etc. Ranke et al conclude that long term treatment of patients with LS promoted growth and, if treatment is started at an early age, there is a considerable potential for achieving height normalisation. Because no patient in our group was treated since early infancy to final height we cannot confirm this opinion. When the growth response to GH treatment in infants with IGHD was compared with that of IGF-1 in infants with LS we found that the infants with IGHD responded faster and better than those with LS. However, the small number of patients and the differences in growth retardation between the two groups makes it difficult to reach a conclusion. Both hormones stimulated linear growth, but GH seemed more effective than IGF-1. One cause may be the greater growth deficit of the infants with LS than those with IGHD, an insufficient dose of IGF-1, or that there is a need for some GH to provide an adequate stem cell population of prechondrocytes to enable full expression of the growth promoting action of IGF-1, as postulated by Green and colleagues and Ohlson et al. All the above findings based on a few clinical studies with small groups of patients and a few experimental studies remain at present controversial. The crucial question is whether there are any, and if so, whether there are sufficient IGF-1 receptors in the “progenitor cartilage zone” of the epiphyseal cartilage to respond to endocrine and exogenous IGF-1. Using the mandibular condyle of 2 day old ICR mice, Maor et al showed that these condyles, which resemble the epiphyseal plates of the long bones, contain IGF-1 and high affinity IGF-1 receptors also in the chondroprogenitor cell layers, which enables them to respond to IGF-1 in vitro. Sims et al, using mice with GH receptor KO, showed that IGF-1 administration stimulates the growth (width) of the tibial growth plate and that IGF-1 has a GH independent effect on the growth plate. These findings are similar to those found when treating hypophysectomised rats with IGF-1. In conclusion, IGF-1 is an important growth hormone, mediating the anabolic and linear growth promoting effect of pituitary GH protein. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.
Document 3 (Title: Urological Complications of Antineoplastic Therapy): Hemorrhagic cystitis represents a significant urological complication of certain antineoplastic agents, characterized by diffuse bladder mucosal inflammation, ulceration, and hemorrhage. Among chemotherapeutic agents, oxazaphosphorine compounds—particularly cyclophosphamide and ifosfamide—are most frequently implicated in this adverse effect. The pathophysiological mechanism involves renal excretion of hepatically-generated metabolites, specifically acrolein, which exerts direct toxicity on the urothelium. After administration, cyclophosphamide undergoes hepatic metabolism via cytochrome P450 enzymes to form 4-hydroxycyclophosphamide, which equilibrates with its tautomer aldophosphamide. While aldophosphamide predominantly undergoes further conversion to phosphoramide mustard (the active antineoplastic compound) and acrolein, a substantial portion of these metabolites remains unchanged and undergoes renal excretion. Within the bladder, acrolein initiates a cascade of inflammatory events including reactive oxygen species generation, nuclear factor-κB activation, and subsequent proinflammatory cytokine release. These processes culminate in urothelial ulceration, neovascularization, and hemorrhage. Clinical manifestations range from microscopic hematuria to frank hemorrhage with clot formation and potential urinary obstruction. Risk factors for development include high cumulative doses, prior pelvic radiation, and concurrent busulfan administration. Preventive strategies center on hyperhydration and concurrent administration of uroprotective agents, particularly 2-mercaptoethane sulfonate sodium (mesna), which binds acrolein in the urinary tract, preventing urothelial toxicity. The timing of mesna administration requires careful coordination with cyclophosphamide dosing to ensure adequate urinary concentrations during peak metabolite excretion. Unlike cyclophosphamide, agents such as methotrexate typically cause nephrotoxicity rather than direct bladder toxicity, while rituximab-associated urological complications generally manifest as infusion reactions rather than hemorrhagic cystitis.

Answer the following multiple-choice question.
Question: A 70-year-old man presents to a medical clinic reporting blood in his urine and lower abdominal pain for the past few days. He is also concerned about urinary frequency and urgency. He states that he recently completed a cycle of chemotherapy for non-Hodgkin lymphoma. Which medication in the chemotherapy regimen most likely caused his symptoms?
Options:
A. Methotrexate
B. Rituximab
C. Cyclophosphamide
D. Prednisone

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ← if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.